Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
- Conditions
- SARS-CoV-2Influenza
- Interventions
- Biological: mRNA-1083
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 932
- Registration Number
- NCT06508320
- Locations
- 🇺🇸
Indago Research & Health Center, Inc., Hialeah, Florida, United States
🇺🇸Cenexel RCA, Hollywood, Florida, United States
🇺🇸Suncoast Research Group, LLC DBA Flourish Research, Miami, Florida, United States
Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
- Conditions
- Maternal OutcomesInfant OutcomesPregnancy
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1192
- Registration Number
- NCT06369272
- Locations
- 🇺🇸
Carelon Research, Newton, Massachusetts, United States
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
- Conditions
- SARS-CoV-2
- Interventions
- Biological: Licensed Spikevax VaccineBiological: Investigational mRNA-1273.815
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT06354998
- Locations
- 🇦🇺
Paratus Canberra, Canberra, Australian Capital Territory, Australia
🇦🇺Holdsworth House, Darlinghurst, New South Wales, Australia
🇦🇺Paratus Brisbane, Brisbane, Queensland, Australia
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 4206
- Registration Number
- NCT06333704
- Locations
- 🇰🇷
Yonseimin Clinic, Wonju, Gangwon-do, Korea, Republic of
🇰🇷Hyundai Clinic, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷Ma Hak ki Family Medicine Clinic, Bucheon, Gyeonggi-do, Korea, Republic of
Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06243770
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
- Conditions
- Myocarditis
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1500
- Registration Number
- NCT06189053
- Locations
- 🇺🇸
Veradigm, Chicago, Illinois, United States
A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Moderna Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- 2023-506963-32-00
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇮🇹Azienda Ospedaliera Universitaria Federico II Di Napoli, Naples, Italy
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06143046
- Locations
- 🇺🇸
SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS, Dothan, Alabama, United States
🇺🇸Abby's Research Institute, Phoenix, Arizona, United States
🇺🇸Watching Over Mothers & Babies, Tucson, Arizona, United States
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
- Conditions
- Cytomegalovirus Infection
- Interventions
- Biological: mRNA-1647Biological: Placebo
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- ModernaTX, Inc.
- Registration Number
- NCT06133010
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 15196685
- Registration Number
- NCT06130345
- Locations
- 🇺🇸
Aetion, Inc, New York, New York, United States